Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell Immunotherapies
Poster Dec 07, 2017
Pete Stecha, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong and Zhi-jie Jey Cheng
Immunotherapy aims to boost a patient’s own immune system to fight disease. In recent years, a variety of immunotherapy strategies aimed at inducing, strengthening or engineering T cell responses have emerged as promising approaches for the treatment of cancer and autoimmune disease.
Here we describe a platform of T cell activation bioassays for the development of CD3 bispecific antibodies and engineered T cell immunotherapies.
Specifically, we developed two bioluminescent reporter-based bioassays to measure T cell activation via CD3 (NFAT-RE) or CD3 + CD28 (IL-2 promoter). These
An Emerging Phenotype of Partial RAG 1/2 Deficiency Among Young Children with Autoimmunity and Viral InfectionsPoster
We describe the natural history of a cohort of 12 patients with confirmed partial RAG1/2 mutations and autoimmunity at a young age. We were seeking the link between viral infections and autoimmunity and tested candidate biomarkers that may reflect the underlying RAG1/2 protein deficiency.READ MORE
Severe Combined Immunodeficiency (SCID) caused by thymic aplasia due to a mutation in TBX1Poster
We report one of the first cases of TBX1 haploinsufficiency causing complete thymic aplasia and SCID.READ MORE
Immunoglobulin G4-Related Disease (IgG4-RD) Presenting As Multiple MyelomaPoster
IgG4-RD is an immune-mediated condition that may affect multiple organs. Allergists/Immunologists should include IgG4-RD in differential diagnosis of subjects with angioedema, blood or tissue eosinophilia, elevated serum IgG4 levels and lymphadenopathy.READ MORE